Validating genomic biomarkers as risk markers for incidence, non-response and recurrence in depression - CAP Study

Validating genomic biomarkers as risk markers for incidence, non-response and recurrence in depression - CAP Study - OptiMD-SP4 CAP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009819

Enrollment

100

Registered

2016-01-13

Start date

2015-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33

Interventions

Group 1: Case/Control study comparing epigenetic modifications (DNA methylation) in CpG-rich regions within candidate genes (ABCB1, FKBP5, P2RX4, P2RX5) between adolescents with and without diagnosis

Eligibility

Sex/Gender

All

Age

8 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children and adolescents of both sexes aged 8 to 18 years, balanced in age and sex distribution between cases and controls; study consent of at least one parent or guardian of the study participant as well as oral and / or written consent of the minor study participant.

Exclusion criteria

Exclusion criteria: Pervasive developmental disorder in study participants (ICD10 F84)

Design outcomes

Primary

Measure	Time frame
Case or control group assignment based on a detailed diagnosis using the Diagnostic Interview for Mental Disorders in Children and Adolescents (Kinder-DIPS). Genetic variations and DNA methylation rates in CpG-rich regions of the genes ABCB1, FKBP5, P2RX4 and P2RX7 will be determined as predictors of the case/control status.	—

Countries

Germany

Contacts

Public ContactGerd Schulte-Körne

Klinikum der UniversitätInstitut für Kinder- und Jugendpsychiatrie

Gerd.Schulte-Koerne@med.uni-muenchen.de089 5160-5901

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026